These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31517176)

  • 1. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.
    Nielsen SM; Eccles DM; Romero IL; Al-Mulla F; Balmaña J; Biancolella M; Bslok R; Caligo MA; Calvello M; Capone GL; Cavalli P; Chan TLC; Claes KBM; Cortesi L; Couch FJ; de la Hoya M; De Toffol S; Diez O; Domchek SM; Eeles R; Efremidis A; Fostira F; Goldgar D; Hadjisavvas A; Hansen TVO; Hirasawa A; Houdayer C; Kleiblova P; Krieger S; Lázaro C; Loizidou M; Manoukian S; Mensenkamp AR; Moghadasi S; Monteiro AN; Mori L; Morrow A; Naldi N; Nielsen HR; Olopade OI; Pachter NS; Palmero EI; Pedersen IS; Piane M; Puzzo M; Robson M; Rossing M; Sini MC; Solano A; Soukupova J; Tedaldi G; Teixeira M; Thomassen M; Tibiletti MG; Toland A; Törngren T; Vaccari E; Varesco L; Vega A; Wallis Y; Wappenschmidt B; Weitzel J; Spurdle AB; De Nicolo A; Gómez-García EB
    JCO Precis Oncol; 2018; 2():. PubMed ID: 31517176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
    Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
    Spurdle AB; Healey S; Devereau A; Hogervorst FB; Monteiro AN; Nathanson KL; Radice P; Stoppa-Lyonnet D; Tavtigian S; Wappenschmidt B; Couch FJ; Goldgar DE;
    Hum Mutat; 2012 Jan; 33(1):2-7. PubMed ID: 21990146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
    Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
    J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector.
    van der Merwe NC; Ntaita KS; Stofberg H; Combrink HM; Oosthuizen J; Kotze MJ
    Front Oncol; 2022; 12():938561. PubMed ID: 36568162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.
    Abdel-Razeq H; Abujamous L; Al-Azzam K; Abu-Fares H; Bani Hani H; Alkyam M; Sharaf B; Elemian S; Tamimi F; Abuhijla F; Edaily S; Salama O; Abdulelah H; Daoud R; Abubaker M; Al-Atary A
    Breast Cancer (Dove Med Press); 2023; 15():1-10. PubMed ID: 36660366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
    Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
    Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
    Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
    Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
    Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.